Nesfatin-1 in human and murine cardiomyocytes: Synthesis, secretion, and mobilization of GLUT-4

Endocrinology

Volumn 154, Issue 12, 2013, Pages 4757-4767

  Feijóo Bandín, Sandra ^a   Rodríguez Penas, Diego ^a   García Rúa, Vanessa ^a   Mosquera Leal, Ana ^a   Otero, Manuel Francisco ^a   Pereira, Eva ^a   Rubio, José ^a   Martínez, Isabel ^a   Seoane, Luisa María ^a   Gualillo, Oreste ^a   Calaza, Manuel ^a   García Caballero, Tomás ^a   Portolés, Manuel ^b   Roselló Lletí, Esther ^b   Diéguez, Carlos ^a   Rivera, Miguel ^b   González Juanatey, José Ramón ^a   Lago, Francisca ^a  

^a Instituto de Salud Carlos III   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AS160 PROTEIN; CELL PROTEIN; GLUCOSE TRANSPORTER 4; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NESFATIN 1; PROTEIN KINASE B; UNCLASSIFIED DRUG; CALCIUM BINDING PROTEIN; DNA BINDING PROTEIN; FAT INTAKE; GLUCOSE; MESSENGER RNA; NERVE PROTEIN; NUCLEOBINDIN;

AGED; ANIMAL CELL; ARTICLE; CARDIOVASCULAR DISEASE; CELL MOTILITY; CONTROLLED STUDY; DIET; FEMALE; GLUCOSE TRANSPORT; HEART; HEART CELL CULTURE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RAT; ANALYSIS; ANIMAL; ANIMAL FOOD; CELL CULTURE; FAT INTAKE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; PHARMACOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMAL FEED; ANIMALS; CALCIUM-BINDING PROTEINS; CELLS, CULTURED; DIET; DIETARY FATS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; HUMANS; MALE; MICE; MYOCYTES, CARDIAC; NERVE TISSUE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 84888241079     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1497     Document Type: Article

References (50)

1. Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443:709-712.
2. Yosten GL, Samson WK. The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist. Am J Physiol Regul Integr Comp Physiol. 2010;298:R1642-R1647.
3. García-Galiano D, Navarro VM, Gaytan F, Tena-Sempere M. Expanding roles of NUCB2/nesfatin-1 in neuroendocrine regulation. J Mol Endocrinol. 2010;45:281-290.
4. Sedbazar U, Maejima Y, Nakata M, Mori M, Yada T. Paraventricular NUCB2/nesfatin-1 rises in synchrony with feeding suppression during early light phase in rats. Biochem Biophys Res Commun. 2013;434:434-438.
5. Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept. 2010;159:72-77.
6. Ramanjaneya M, Chen J, Brown JE, et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology. 2010;151:3169-3180.
7. Tsuchiya T, Shimizu H, Yamada M, et al. Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in nonobese males. Clin Endocrinol (Oxf). 2010;73:484-490.
8. Zhang Z, Li L, Yang M, Liu H, Boden G, Yang G. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2012;120:91-95.
9. Baar O, Akbal E, Köklü S, et al. A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease. Scand J Clin Lab Invest. 2012;72:479-483.
10. Shimizu H, Oh-I S, Hashimoto K, et al. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology. 2009;150:662-671.
11. Maejima Y, Sedbazar U, Suyama S, et al. Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway. Cell Metab. 2009;10:355-365.
12. Stengel A, Goebel M, Taché Y. Nesfatin-1: a novel inhibitory regulator of food intake and body weight. Obes Rev. 2011;12:261-271.
13. Gonzalez R, Perry RL, Gao X, et al. Nutrient responsive nesfatin-1 regulates energy balance and induces glucose-stimulated insulin secretion in rats. Endocrinology. 2011;152:3628-3637.
14. Könczöl K, Pintér O, Ferenczi S, et al. Nesfatin-1 exerts long-term effect on food intake and body temperature. Int J Obes (Lond). 2012;36:1514-1521.
15. Miyata S, Yamada N, Kawada T. Possible involvement of hypothalamic nucleobindin-2 in hyperphagic feeding in Tsumura Suzuki obese diabetes mice. Biol Pharm Bull. 2012;35:1784-1793.
16. Foo KS, Brauner H, Ostenson CG, Broberger C. Nucleobindin-2/nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state. J Endocrinol. 2010;204:255-263.
17. Riva M, Nitert MD, Voss U, et al. Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects. Cell Tissue Res. 2011;346:393-405.
18. Su Y, Zhang J, Tang Y, Bi F, Liu JN. The novel function of nesfatin-1: anti-hyperglycemia. Biochem Biophys Res Commun. 2010;391:1039-1042.
19. Yang M, Zhang Z, Wang C, et al. Nesfatin-1 action in the brain increases insulin sensitivity through Akt/AMPK/TORC2 pathway in diet-induced insulin resistance. Diabetes. 2012;61:1959-1968.
20. Chen X, Dong J, Jiang ZY. Nesfatin-1 influences the excitability of glucosensing neurons in the hypothalamic nuclei and inhibits the food intake. Regul Pept. 2012;177:21-26.
21. Stengel A, Goebel-Stengel M, Jawien J, Kobelt P, Taché Y, Lambrecht NW. Lipopolysaccharide increases gastric and circulating NUCB2/nesfatin-1 concentrations in rats. Peptides. 2011;32:1942-1947.
22. Stengel A, Goebel M, Yakubov I, et al. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology. 2009;150:232-238.
23. García-Galiano D, Pineda R, Ilhan T, et al. Cellular distribution, regulated expression, and functional role of the anorexigenic peptide, NUCB2/nesfatin-1, in the testis. Endocrinology. 2012;153:1959-1971.
24. Osaki A, Shimizu H, Ishizuka N, Suzuki Y, Mori M, Inoue S. Enhanced expression of nesfatin/nucleobindin-2 in white adipose tissue of ventromedial hypothalamus-lesioned rats. Neurosci Lett. 2012;521:46-51.
25. Angelone T, Filice E, Pasqua T, et al. Nesfatin-1 as a novel cardiac peptide: identification, functional characterization, and protection against ischemia/reperfusion injury. Cell Mol Life Sci. 2013;70:495-509.
26. Yosten GL, Samson WK. Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol. 2009;297:R330-R336.
27. Yamawaki H, Takahashi M, Mukohda M, Morita T, Okada M, Hara Y. A novel adipocytokine, nesfatin-1 modulates peripheral arterial contractility and blood pressure in rats. Biochem Biophys Res Commun. 2012;418:676-681.
28. Mimee A, Smith PM, Ferguson AV. Nesfatin-1 influences the excitability of neurons in the nucleus of the solitary tract and regulates cardiovascular function. Am J Physiol Regul Integr Comp Physiol. 2012;302:R1297-R1304.
29. García-Rúa V, Otero MF, Lear PV, et al. Increased expression of fatty-acid and calcium metabolism genes in failing human heart. PLoS One. 2012;7:e37505.
30. González-Juanatey JR, Iglesias MJ, Alcaide C, Piñeiro R, Lago F. Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of α1-adrenergic blockade. Circulation. 2003;107:127-131.
31. Lear PV, Iglesias MJ, Feijóo-Bandín S, et al. Des-acyl ghrelin has specific binding sites and different metabolic effects from ghrelin in cardiomyocytes. Endocrinology. 2010;151:3286-3298.
32. Slot JW, Garruti G, Martin S, et al. Glucose transporter (GLUT-4) is targeted to secretory granules in rat atrial cardiomyocytes. J Cell Biol. 1997;137:1243-1254.
33. Lu H, Buchan RJ, Cook SA. MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc Res. 2010;86:410-420.
34. Waller AP, George M, Kalyanasundaram A, et al. GLUT12 functions as a basal and insulin-independent glucose transporter in the heart. Biochim Biophys Acta. 2013;1832:121-127.
35. Pu J, Peng G, Li L, Na H, Liu Y, Liu P. Palmitic acid acutely stimulates glucose uptake via activation of Akt and ERK1/2 in skeletal muscle cells. J Lipid Res. 2011;52:1319-1327.
36. Steinbusch LK, Schwenk RW, Ouwens DM, Diamant M, Glatz JF, Luiken JJ. Subcellular trafficking of the substrate transporters GLUT4 and CD36 in cardiomyocytes. Cell Mol Life Sci. 2011;68:2525-2538.
37. Lago F, Dieguez C, Gómez-Reino J, Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol. 2007;3:716-724.
38. Turer AT, Hill JA, Elmquist JK, Scherer PE. Adipose tissue biology and cardiomyopathy: translational implications. Circ Res. 2012;111:1565-1577.
39. Kronebusch PJ, Singer SJ. The microtubule-organizing complex and the Golgi apparatus are co-localized around the entire nuclear envelope of interphase cardiac myocytes. J Cell Sci. 1987;88:25-34.
40. McFarland TP, Milstein ML, Cala SE. Rough endoplasmic reticulum to junctional sarcoplasmic reticulum trafficking of calsequestrin in adult cardiomyocytes. J Mol Cell Cardiol. 2010;49:556-564.
41. Nakata M, Manaka K, Yamamoto S, Mori M, Yada T. Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca2+ influx through L-type channels in mouse islet β-cells. Endocr J. 2011;58:305-313.
42. Brailoiu GC, Dun SL, Brailoiu E, et al. Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology. 2007;148:5088-5094.
43. Tagaya Y, Osaki A, Miura A, et al. Secreted nucleobindin-2 inhibits 3T3-L1 adipocyte differentiation. Protein Pept Lett. 2012;19:997-1004.
44. Cartee GD, Wojtaszewski JF. Role of AKT substrate of 160 kDa in insulin-stimulated and contraction-stimulated glucose transport. Appl Physiol Nutr Metab. 2007;32:557-566.
45. Nakata M, Yada T. Role of NUBC2/nesfatin-1 in glucose control: diverse functions in islets, adipocytes and brain [published online ahead of print March 25, 2013; DOI: 10.2174/138161281131900642]. Curr Pharm Des.
46. Bruss MD, Arias EB, Lienhard GE, Cartee GD. Increased phosphorylation of AKT substrate of 160 kDa (AS160) in rat skeletal muscle in response to insulin or contractile activity. Diabetes. 2005;54:41-50.
47. Samovski D, Su X, Xu Y, Abumrad NA, Stahl PD. Insulin and AMPK regulate FA translocase/CD36 plasma membrane recruitment in cardiomyocytes via Rab GAP AS160 and Rab8a Rab GTPase. J Lipid Res. 2012;53:709-717.
48. Kohno D, Nakata M, Maejima Y, et al. Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology. 2008;149:1295-1301.
49. Li Z, Xu G, Li Y, Zhao J, Mulholland MW, Zhang W. mTOR-dependent modulation of gastric nesfatin-1/NUCB2. Cell Physiol Biochem. 2012;29:493-500.
50. Yamada M, Horiguchi K, Umezawa R, et al. Troglitazone, a ligand of peroxisome proliferator-activated receptor-γ, stabilizes NUCB2 (nesfatin) mRNA by activating the ERK1/2 pathway: isolation and characterization of the human NUCB2 gene. Endocrinology. 2010;151:2494-2503.